- Home
- URGN vs SHBI Comparison
URGN vs SHBI Comparison
Compare URGN & SHBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- SHBI
- Stock Information
- Founded
- URGN 2004
- SHBI 1876
- Country
- URGN United States
- SHBI United States
- Employees
- URGN N/A
- SHBI N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- SHBI Major Banks
- Sector
- URGN Health Care
- SHBI Finance
- Exchange
- URGN Nasdaq
- SHBI Nasdaq
- Market Cap
- URGN 465.9M
- SHBI 528.2M
- IPO Year
- URGN 2017
- SHBI N/A
- Fundamental
- Price
- URGN $10.27
- SHBI $15.49
- Analyst Decision
- URGN Strong Buy
- SHBI Buy
- Analyst Count
- URGN 5
- SHBI 2
- Target Price
- URGN $44.50
- SHBI $20.00
- AVG Volume (30 Days)
- URGN 487.3K
- SHBI 93.1K
- Earning Date
- URGN 03-13-2025
- SHBI 01-29-2025
- Dividend Yield
- URGN N/A
- SHBI 3.10%
- EPS Growth
- URGN N/A
- SHBI 215.95
- EPS
- URGN N/A
- SHBI 1.23
- Revenue
- URGN $89,363,000.00
- SHBI $193,048,000.00
- Revenue This Year
- URGN $13.39
- SHBI N/A
- Revenue Next Year
- URGN $45.06
- SHBI $7.29
- P/E Ratio
- URGN N/A
- SHBI $12.55
- Revenue Growth
- URGN 15.64
- SHBI 71.02
- 52 Week Low
- URGN $9.78
- SHBI $10.06
- 52 Week High
- URGN $20.70
- SHBI $17.61
- Technical
- Relative Strength Index (RSI)
- URGN 39.53
- SHBI 45.70
- Support Level
- URGN $10.12
- SHBI $15.25
- Resistance Level
- URGN $10.96
- SHBI $15.61
- Average True Range (ATR)
- URGN 0.57
- SHBI 0.35
- MACD
- URGN -0.01
- SHBI -0.02
- Stochastic Oscillator
- URGN 24.75
- SHBI 59.15
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About SHBI Shore Bancshares Inc
Shore Bancshares Inc is a financial holding company. It offers personalized banking, insurance, and investment services to families and businesses in the Mid-Atlantic region. It operates in two business segments - community banking and mortgage banking. Community banking is conducted through the Bank and involves delivering a broad range of financial services, including lending and deposit-taking, to individuals and commercial enterprises, it also includes treasury and administrative functions. Mortgage banking is conducted through the Bank's secondary marketing department and involves originating first and second-lien residential mortgages for sale in the secondary market.